Results 281 to 290 of about 174,356 (352)

Targeting the protein-protein interaction between the CDC37 cochaperone and client kinases by an allosteric RAF dimer breaker. [PDF]

J Biol Chem
Yu A, Banerjee S, Malasani S, Towolawi B, Liu Z, Wang Z.   +5 more
europepmc   +1 more source

Fig S2 from Preclinical Activity of the Type II RAF Inhibitor Tovorafenib in Tumor Models Harboring Either a BRAF Fusion or an NF1 Loss-of-Function Mutation

Shubhra Rastogi, Samantha Perino, Madhu Lal-Nag, Yujin Wang, Samuel C. Blackman, Eleni Venetsanakos   +5 more
openalex   +1 more source

Genomic signature driving preinvasive to invasive processes in stage I lung adenocarcinoma

International Journal of Cancer, Volume 158, Issue 7, Page 1975-1988, 1 April 2026.
What's new? The progression of lung cancer from minimally invasive adenocarcinoma (MIA) to invasive adenocarcinoma (IA) is a complex process involving molecular and microenvironment changes. Key molecular events that drive the invasion process, however, remain poorly characterized. In this comparison of gene profiles and differentially mutated genes in
Biqin Mou, Yishan Duan, Jing Wang, Tiantian Li, Yuwei Huo, Xia Xiao, Conghui Cui, Zhujun Deng, Qiongxia Hu, Juan Jiang, Yiwei Liang, Sifen Lu, Xintong Tao, Kang Xie, Xinru Xiong, Niu Zhu, Liyun Bi, Faqiang Zhang, Weimin Li, Bojiang Chen   +19 more
wiley   +1 more source

The Frontier of Melanoma Treatment: Defeating Immunotherapy Resistance-A Systematic Review. [PDF]

Oncol Res
Mozga K, Synowiecka O, Rydzyk I, Marek A, Wieczorek E, Petniak A, Gil-Kulik P.   +6 more
europepmc   +1 more source

Extramedullary Disease—Achilles Heel in Myeloma?

American Journal of Hematology, Volume 101, Issue 3, Page 521-536, March 2026.
ABSTRACT Despite advances in therapy, extramedullary disease (EMD) remains an aggressive form of multiple myeloma associated with poor outcomes. Patients with true EMD, in which plasmacytomas have become completely independent of bone, have a particularly poor prognosis. The pathogenesis of EMD is driven by complex mechanisms involving loss of adhesion
Shaji Kumar, Joshua Richter, Saad Z. Usmani, Yael C. Cohen, Jing Christine Ye, María‐Victoria Mateos, Vania Hungria, Elena Zamagni   +7 more
wiley   +1 more source

PROTAC-mediated degradation of Bcl-xL potentiates target therapy in preclinical melanoma models. [PDF]

J Exp Clin Cancer Res
Valentini E, Gentile G, Di Martile M, D'Aguanno S, Brignone M, Di Stefano AM, Di Caprio M, Melucci E, Botti C, Pelle F, Ortolano A, Fattore L, Mancini R, Ciliberto G, Rotili D, Del Bufalo D.   +15 more
europepmc   +1 more source

Non‐RASopathy Genetic Syndromes Identified as the Molecular Cause of Disease in Patients Previously Diagnosed With Noonan Syndrome

American Journal of Medical Genetics Part A, Volume 200, Issue 3, Page 661-672, March 2026.
ABSTRACT Noonan Syndrome (NS) is a clinically and genetically heterogeneous condition characterized by typical facial dysmorphisms, short stature, congenital heart defects, and developmental delays. While variants in genes such as PTPN11, SOS1, and RAF1 account for most genetically confirmed cases, diagnosis is challenging due to phenotypic overlap ...
Gabriela Jeesoo Kim, Alexsandra Christianne Malaquias, Debora Romeo Bertola, Raissa Carneiro Rezende, Laurana De Polli Cellin, Lucas Vieira Lacerda Pires, Ana Maria Santillan‐Vasconez, Antônio Marcondes Lerario, Renata da Cunha Scalco, Alexander Augusto de Lima Jorge   +9 more
wiley   +1 more source

Local Anesthetics in Cancer: Mechanisms and Translational Perspectives

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Local anesthetics demonstrate multifaceted antitumor effects that collectively contribute to cancer suppression. Beyond canonical sodium channel blockade, these agents exert the following pharmacological actions: inhibition of tumor cell proliferation, suppression of migration and invasion, induction of proapoptotic pathways, attenuation of ...
Wan‐li Wang, Tu Huang, Yi‐hang Hao, Min Zheng, Xin‐hua Liang   +4 more
wiley   +1 more source

Dabrafenib plus trametinib in an elderly patient with BRAF V600E-mutant advanced pancreatic adenocarcinoma: A case report. [PDF]

Front Oncol
Liu L, Zhu X, Guo Y, Tang M, Zhou W, Chen B.   +5 more
europepmc   +1 more source